Genomics of smoking exposure and cessation: Lessons for cancer prevention and treatment

Cancer Prevention Research

Volumn 1, Issue 2, 2008, Pages 80-83

  Penning, Trevor M ^a,b   Lerman, Caryn ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ANIMAL; BIOLOGICAL MODEL; EXPOSURE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HUMAN; MOUSE; MOUSE MUTANT; NEOPLASM; NOTE; PHYSIOLOGY; SMOKING; SMOKING CESSATION; VALIDATION STUDY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; INHALATION EXPOSURE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NEOPLASMS; SMOKING; SMOKING CESSATION; VALIDATION STUDIES AS TOPIC;

EID: 59049105837     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0047     Document Type: Review

References (57)

1. CDC. Cigarette smoking among adults-United States, 2004. MMWRMorb Mortal Wkly Rep 2005;54:1121-4.
2. MacKay M, Eriksen M. The tobacco atlas. World Health Organization; 2001.
3. Lerman C, Lesage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007;9: 746-62.
4. Schnoll R, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 2006;11:1-16.
5. Gritz E, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005; 14:2287-93.
6. Gumus ZH, Du B, Kacker A, et al. Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res. In press.
7. Zhang L, Lee JJ, Tang H, et al. Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev Res. In press.
8. Nagaraj N, Beckers S, Meansh JK, et al. Cigarette smoke condensate induces cytochrome P450 and aldo keto reductases in oral cancer cells. Toxicol Lett 2006;165:182-94.
9. Fukumoto S-I, Yamauchi N, Moriguchi H, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005;11:1776-85.
10. Woenckhaus M, Klein-Hitpass L, Grepmeier U, et al. Smoking and cancer-related gene expression in bronchial epithelium and non-small cell lung cancer. J Pathol 2006;210:192-204.
11. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 2004;101:10143-8.
12. Beane J, Sebastiani P, Liu G, et al. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol 2007;8:R201.
13. Till M, Riebniger D, Schmitz HJ, et al. Potency of various polycyclic aromatic hydrocarbons as inducers of CYP1A1 in rat hepatocyte cultures. Chem Biol Interact 1999;117:135-50.
14. Sutter TR, Tang YM, Hayes CL, et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 1994;269:13092-9.
15. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res 1996; 56:2979-84.
16. Palackal NT, Lee S-H, Harvey RG, et al. Activation of polycyclic aromatic hydrocarbon transdihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem 2002;277:24799-808.
17. Denison MS, Fisher JM, Whitlock JP. The DNA recognition site for the dioxin-Ah receptor complex. Nucleotide sequence and functional analysis. J Biol Chem 1988;263:17221-4.
18. Denison MS, Fisher JM, Whitlock JP. Protein-DNA interactions at recognition sites for the dioxin-Ah receptor complex. J Biol Chem 1989;264:16478-82.
19. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons. G.H.A. Clowes Memorial Lecture. Cancer Res 1982;42:4875-917.
20. Gelboin HV. Benzo[a]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed function oxidases and related enzymes. Physiol Rev 1980;60:1107-66.
21. Uno S, Dalton TP, Shertzer HG, et al. Benzo[a] pyrene-induced toxicity: paradoxical protection in Cyp1a1(-/-) knockout mice having increased heaptic B[a]P-DNA adduct levels. Biochem Biophys Res Commun 2001;289:1049-56.
22. Uno S, Dalton TP, Derkenne S, et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 2004; 65:1225-37.
23. Uno S, Dalton TP, Dragin N, et al. Oral benzo[a] pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total body burden and clearance rate. Mol Pharmacol 2006;69:1103-14.
24. Ruan Q, Gelhaus SL, Penning TM, et al. Aldoketo reductase- and cytochrome P450-dependent formation of benzo[a]pyrene-derived DNA adducts in human bronchoalveolar cells. Chem Res Toxicol 2007;20:424-31.
25. Smithgall TE, Harvey RG, Penning TM. Spectroscopic identification of ortho-quinones as the products of polycyclic aromatic trans-dihydrodiol oxidation catalyzed by dihydrodiol dehydrogenase. A potential route of proximate carcinogen metabolism. J Biol Chem 1988;263:1814-20.
26. Burczynski ME, Harvey RG, Penning TM. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a] pyrene-7,8-dione. Biochemistry 1998;37:6781-90.
27. Park J-H, Troxel AB, Harvey RG, et al. Polycyclic aromatic hydrocarbon (PAH) o-quinones produced by the aldo-keto reductases (AKRs) generate abasic sites, oxidized pyrimidines, and 8-oxo-dGuo via reactive oxygen species. Chem Res Toxicol 2006; 19:719-28.
28. Nakabeppu Y, Sakumi K, Sakamoto K, et al. Mutagenesis and carcinogenesis by oxidized nucleic acids. Biol Chem 2006;387:373-9.
29. Burczynski ME, Penning TM. Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor. Cancer Res 2000;60:908-15.
30. Jiang H, Vudathala DK, Blair IA, et al. Competing roles of aldo-keto reductase 1A1 and cytochrome P4501B1 in benzo[a]pyrene-7,8-diol activation in human bronchoalveolar H358 cells: role of AKRs in P4501B1 induction. Chem Res Toxicol 2006;19: 68-78.
31. Burczynski ME, Lin H-K, Penning TM. Isoformspecific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenases. Cancer Res 1999;59:607-14.
32. Lou H, Du S, Ji Q, et al. Induction of AKR1C2 by Phase II inducers: identification of a distal consensus antioxidant response element regulated by Nrf2. Mol Pharmacol 2006;69:1662-72.
33. Shin S, Wakabayashi N, Misra V, et al. Nrf2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol Cell Biol 2007;27: 7188-97.
34. Penning TM, Drury J. Human aldo-keto reductases. Function, gene regulation and single nucleotide polymorphisms. Arch Biochem Biophys 2007; 464:241-50.
35. Sreerama L, Sladek NE. Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constititutively up-regulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5′-upstream regions of these genes. Chem Biol Interact 2001;130-2: 247-69.
36. Esterbauer HM, Schauer RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondial-dehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
37. Esterbauer H. Cytotoxocity and genotoxicity of lipid oxidation products. Am J Clin Nutr 1993;57: 779-85S.
38. Cao D, Fan ST, Chung SSM. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998;273:11429-35.
39. Yan R, Zu X, Ma J. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cells: implication for cancer intervention. Int J Cancer 2007;121:2301-6.
40. Gallego O, Belyaeva OV, Porte S, et al. Comparative functional analysis of human medium chain dehydrogenasess, short-chain dehydrogenases and aldo-keto reductases with retinoids. Biochem J 2006;399:101-9.
41. Le Q, Dawson MI, Soprano DR, Soprano KJ. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene 2000;19:1457-65.
42. Brabender J, Danneberg KD, Metzger R, et al. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res 2002;8:438-43.
43. Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food Chem Toxicol 1999;37: 973-9.
44. Penning TM, Talalay P. Inhibition of a major NAD (P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. Proc Natl Acad Sci U S A 1983;80:4504-8.
45. The α Tocopherol-β Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-35.
46. Omenn G, Goodman GE, Thronquist MD, et al. Effects of combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
47. Mayne ST, Lippman SM. Cigarettes: a smoking gun in cancer chemoprevention. J Natl Cancer Inst 2005;97:1319-21.
48. Woodson K, Tangrea JA, Barrett MJ, et al. Serum α-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst 1999;91: 1738-43.
49. Hamilton M, Wolf JL, R usk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-71.
50. Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13:3731-7.
51. Ciaccio PJ, Shen H, Jaiswal AK, et al. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors. Mol Pharmacol 1995;48:639-47.
52. Hsu N-Y, Ho H-C, Chow K-C, et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 2001;61:2727-31.
53. Deng HB, Parekh HK, Chow KC, et al. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 2002;277:5035-43.
54. Deng HB, Adikari M, Parekh HK, et al. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol 2004;54:301-7.
55. Beane J, Sebastiani P, Whitfield TH, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res. In press.
56. McBride CM, Bepler G, Lipkus IM, et al. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev 2002;11:521-8.
57. Uhl GR, Liu QR, Drgon T, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association results. Arch Gen Psychiatry 2008. In press.